Flagship Pioneering

Etiome is a biotechnology company that specializes in the development of innovative medicines, known as Biostaged Medicines. These medicines are designed to map and understand the progression of diseases with high resolution over time. Etiome's approach enables the healthcare industry to intervene at early stages of disease, preventing further progression and potentially halting debilitating and irreversible conditions.

Ampersand Biomedicines is a biopharmaceutical company that focuses on developing innovative programming therapeutics aimed at targeting diseases directly at their site of occurrence. The company employs its Address, Navigate, Design (AND)™ Platform to create localized treatments that enhance precision in disease management. By integrating a localizing element with a carefully selected actuator for disease modification, Ampersand Biomedicines enables researchers to address a broad spectrum of diseases across various body systems. This approach allows for a tailored therapeutic response, potentially improving the efficacy of treatments and advancing the field of precision medicine.

Lila Sciences is a technology company that specializes in accelerating scientific research. It develops artificial intelligence-driven tools and autonomous labs, focusing on life sciences, chemical sciences, and materials sciences. The platform aims to enhance research efficiency and facilitate scientific discoveries by processing vast amounts of data, designing experiments, generating hypotheses, and testing them in real-world environments. This enables scientists to achieve breakthroughs and innovate more rapidly.

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

Mirai Bio is a biotechnology company that has created an AI-driven, open platform to overcome challenges in the development and manufacturing of genetic medicines. Their platform offers tools for biological and biomedical research, including data compilation, analysis algorithms, and scientific article search, focusing on DNA, RNA, and protein sequence analysis. This enables researchers to efficiently analyze data, derive insights from biological sequences, and accelerate their research progress.

Prologue Medicines creates transformative medicines by systematically discovering and evaluating viral proteins and their unique features.

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Harbinger Health is a biotechnology company focused on the early detection of cancer through an innovative blood testing model. By integrating artificial intelligence and machine learning with biological insights, Harbinger Health aims to identify cancer at an early stage, even before symptoms become apparent. The company's approach is designed to facilitate low-cost, multi-cancer blood tests, which could significantly enhance diagnostic capabilities in healthcare. Through its advanced technology, Harbinger Health seeks to improve cancer outcomes by enabling timely intervention and diagnosis.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Alltrna is a biotechnology company focused on advancing tRNA biology to develop innovative therapeutics for a wide range of diseases. By leveraging its proprietary tRNA platform, the company seeks to understand the intricate mechanisms of tRNA and its role in translating mRNA into proteins. Alltrna employs artificial intelligence and machine learning tools to decode the tRNA language, facilitating the creation of diverse, programmable molecules with significant therapeutic potential. This approach aims to enable the correction of various diseases by harnessing the capabilities of tRNA biology.

Empress Therapeutics is an early-stage biotechnology company focused on drug development and gaining new molecular insights into health and disease. The company utilizes a proprietary bio platform that integrates evolutionary principles, human molecular and genetic data, and artificial intelligence to identify advanced starting points in endogenous drug-like molecules. This innovative approach aims to enable clinicians to address a variety of serious unmet medical needs through the development of small-molecule drug candidates.

Metaphore Biotechnologies use biomimicry and machine learning to unveil the revolutionary medicinal potential of functional molecular mimics. The MIMiCTM platform, developed by the business, is a computationally driven bio platform for developing novel therapies in which function, specificity, and selectivity may be optimized. Metaphore is dedicated to uncovering previously inaccessible pharmacological targets and achieving breakthroughs that exceed today's medications for maximum patient effect.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative gene therapies utilizing its proprietary Anellovector platform. This platform, based on the human commensal virome, addresses several limitations of existing gene therapies, including restricted access to diverse tissues, challenges in redosing, risks of genomic integration, and issues with tolerability. Founded in 2017 and previously known as VL46, Inc., Ring Therapeutics aims to expand the applications of gene therapy beyond traditional gene replacement. By enabling a broader range of therapeutic modalities and mechanisms, the company seeks to treat a variety of previously inaccessible diseases, including genetic disorders, ophthalmology, oncology, and metabolic conditions.

Ampersand Biomedicines is a biopharmaceutical company that focuses on developing innovative programming therapeutics aimed at targeting diseases directly at their site of occurrence. The company employs its Address, Navigate, Design (AND)™ Platform to create localized treatments that enhance precision in disease management. By integrating a localizing element with a carefully selected actuator for disease modification, Ampersand Biomedicines enables researchers to address a broad spectrum of diseases across various body systems. This approach allows for a tailored therapeutic response, potentially improving the efficacy of treatments and advancing the field of precision medicine.

Montai Health is dedicated to improving health outcomes by harnessing nature's power through advanced digital technology to treat and prevent chronic diseases. The company is focused on developing Anthromolecule medications, which are based on a unique class of compounds with a proven history of safe human use. By creating the world's first Anthromolecule Bioactivity Atlas, Montai Health aims to map the connections to biological pathways associated with various diseases, enabling the rapid and repeatable development of safe and effective treatments. Additionally, the company emphasizes molecular nutrition research to protect and enhance human health sustainably, employing a multidisciplinary approach that incorporates machine learning, big data, multi-omics, and high-throughput screening. This comprehensive strategy positions Montai Health to address global health challenges and improve patient recovery outcomes.

Cellarity Inc is a therapeutics company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines through the analysis of cellular behaviors. Established in 2017, the company employs advanced genomic technologies, data science, and artificial intelligence to create a comprehensive platform that digitizes molecular information within cells. This approach allows Cellarity to investigate how cells function in both health and disease, aiming to address the complexities of various medical conditions. By leveraging single-cell technologies and machine learning, the company seeks to enhance the success rate and efficiency of drug discovery, ultimately designing therapies that effectively target the intricate dynamics of cellular behavior.

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Apriori Bio is a health security company dedicated to safeguarding humanity from viral threats. Utilizing an innovative technology platform, the company designs variant-resilient vaccines and develops antibody drugs aimed at addressing both existing and potential viral variants. By providing real-time insights into the landscape of these threats, Apriori Bio enhances preparedness for future outbreaks. Through its focused approach, the company seeks to deliver durable protection against rapidly evolving viruses, contributing to global health security.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

Vesalius Therapeutics is a biotechnology company dedicated to advancing the understanding and treatment of diseases responsible for the majority of human illnesses. The company has developed a platform that connects clinical patterns with the interactions of various genes, allowing for the identification of genetic circuits that contribute to disease. By creating proprietary, patient-derived, cell-based experimental models, Vesalius Therapeutics screens and characterizes drug candidates aimed at restoring the functionality of these genetic circuits. This innovative approach empowers healthcare practitioners to identify previously unrecognized clinical patterns among patient populations, ultimately enhancing the potential for targeted and effective treatments.

Harbinger Health is a biotechnology company focused on the early detection of cancer through an innovative blood testing model. By integrating artificial intelligence and machine learning with biological insights, Harbinger Health aims to identify cancer at an early stage, even before symptoms become apparent. The company's approach is designed to facilitate low-cost, multi-cancer blood tests, which could significantly enhance diagnostic capabilities in healthcare. Through its advanced technology, Harbinger Health seeks to improve cancer outcomes by enabling timely intervention and diagnosis.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Alltrna is a biotechnology company focused on advancing tRNA biology to develop innovative therapeutics for a wide range of diseases. By leveraging its proprietary tRNA platform, the company seeks to understand the intricate mechanisms of tRNA and its role in translating mRNA into proteins. Alltrna employs artificial intelligence and machine learning tools to decode the tRNA language, facilitating the creation of diverse, programmable molecules with significant therapeutic potential. This approach aims to enable the correction of various diseases by harnessing the capabilities of tRNA biology.

CIBO Technologies, Inc. is a company that specializes in developing software products to model and simulate agricultural ecosystems, aimed at enhancing sustainable practices in agriculture. Its key offerings include Continuum DB, a distributed database for spatio-temporal modeling; BarnCAT, a computational agronomy toolkit; WhetherRain, an integrated weather simulation tool; and DirtPatch, a platform for environmental reconstruction. Additionally, CIBO provides TerraFarm for planetary-scale simulations and the Land Intelligence platform, which generates insights on agricultural parcels while offering access to publicly available data for various stakeholders in the agriculture sector. The company's solutions are designed to support a wide range of crops and serve multiple industries, including farm services, agribusiness, and sustainability. Founded in 2014 and based in Cambridge, Massachusetts, with additional offices in Saint Louis, East Lansing, and Minneapolis, CIBO aims to advance food system resilience and improve grower outcomes in the face of climate change.

YourBio Health is focused on transforming the blood sampling and testing process by creating innovative products that enhance the interface between diagnostic medicine and healthcare consumers. The company has developed a unique blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy technology, this push-button device can be applied to the upper arm, enabling individuals to collect their blood with a simple press of a button. This one-step process is designed to eliminate barriers to acquiring critical diagnostic information, facilitating improved diagnoses and health outcomes. By making diagnostic testing accessible almost anywhere, YourBio Health aims to empower patients in their healthcare journey and enhance the overall experience for both patients and clinicians.

Laronde is a biotechnology company that specializes in developing an eRNA-based therapeutic platform designed to express a variety of proteins within the body. Founded in 2017 by Flagship Labs, Laronde's innovative Endless RNA technology is engineered to be persistent and non-immunogenic, allowing for repeat dosing and offering flexibility in both formulation and delivery. This platform aims to enhance the predictability and efficacy of new medicines, facilitating the development of therapeutics that can address a wide range of diseases. As Laronde continues to scale its operations, it focuses on advancing multiple programs simultaneously, positioning itself as a key player in the future of medicine.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative gene therapies utilizing its proprietary Anellovector platform. This platform, based on the human commensal virome, addresses several limitations of existing gene therapies, including restricted access to diverse tissues, challenges in redosing, risks of genomic integration, and issues with tolerability. Founded in 2017 and previously known as VL46, Inc., Ring Therapeutics aims to expand the applications of gene therapy beyond traditional gene replacement. By enabling a broader range of therapeutic modalities and mechanisms, the company seeks to treat a variety of previously inaccessible diseases, including genetic disorders, ophthalmology, oncology, and metabolic conditions.

Invaio Sciences, Inc. is a multi-platform technology company headquartered in Cambridge, Massachusetts, with additional offices in Durham, North Carolina; Basel, Switzerland; and São Paulo, Brazil. Established in 2016, the company focuses on harnessing advanced sciences to address critical challenges in agriculture, nutrition, and the environment. Invaio's innovative technologies aim to reduce pesticide usage globally by enhancing the understanding of insect physiology and interdependent natural systems. By developing solutions that are both effective against pests and safe for beneficial species, Invaio seeks to create a positive impact on agriculture and human and animal health, positioning itself at the forefront of transformative practices in these fields.

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

Laronde is a biotechnology company that specializes in developing an eRNA-based therapeutic platform designed to express a variety of proteins within the body. Founded in 2017 by Flagship Labs, Laronde's innovative Endless RNA technology is engineered to be persistent and non-immunogenic, allowing for repeat dosing and offering flexibility in both formulation and delivery. This platform aims to enhance the predictability and efficacy of new medicines, facilitating the development of therapeutics that can address a wide range of diseases. As Laronde continues to scale its operations, it focuses on advancing multiple programs simultaneously, positioning itself as a key player in the future of medicine.

Repertoire Immune Medicines, Inc. is a clinical stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company focuses on harnessing the power of T cells to develop innovative treatments for cancer, autoimmune diseases, and infectious diseases. By utilizing autologous T cells that are primed against specific cancer antigens and tethered to IL-15, Repertoire Immune Medicines aims to unlock and direct the human immune system to effectively prevent and treat various conditions. The company also specializes in characterizing T cell receptor (TCR)-antigen pairs and rationally designing targeted immune medicines, thereby enhancing the potential for effective therapies in serious health challenges.

Omega Therapeutics, Inc. is a development-stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in developing genomic medicines aimed at curing diseases through precision tuning of the human genome. It utilizes its proprietary epigenomic programming platform to engineer a new class of programmable epigenetic medicines known as Omega Epigenomic Controllers. These controllers are designed to selectively regulate genomic activity, allowing for the downregulation or upregulation of genes to achieve therapeutic effects. Omega Therapeutics seeks to transform human medicine by harnessing the natural capacity of the genome to treat and cure various diseases.

Cellarity Inc is a therapeutics company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines through the analysis of cellular behaviors. Established in 2017, the company employs advanced genomic technologies, data science, and artificial intelligence to create a comprehensive platform that digitizes molecular information within cells. This approach allows Cellarity to investigate how cells function in both health and disease, aiming to address the complexities of various medical conditions. By leveraging single-cell technologies and machine learning, the company seeks to enhance the success rate and efficiency of drug discovery, ultimately designing therapies that effectively target the intricate dynamics of cellular behavior.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

Omega Therapeutics, Inc. is a development-stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in developing genomic medicines aimed at curing diseases through precision tuning of the human genome. It utilizes its proprietary epigenomic programming platform to engineer a new class of programmable epigenetic medicines known as Omega Epigenomic Controllers. These controllers are designed to selectively regulate genomic activity, allowing for the downregulation or upregulation of genes to achieve therapeutic effects. Omega Therapeutics seeks to transform human medicine by harnessing the natural capacity of the genome to treat and cure various diseases.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing functional cures for patients with chronic diseases. Founded in 2015, the company aims to create immune-protected, engineered human cells that restore normal physiological functions without the risk of fibrosis or immune rejection. Its lead product candidate, SIG-001, is currently in Phase I/II clinical trials for preventing bleeding episodes in patients with moderate to severe Hemophilia A. Additionally, Sigilon is advancing other candidates, including SIG-005, which targets non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells for treating type 1 diabetes. The company's innovative Shielded Living Therapeutics platform leverages advances in cell engineering and proprietary biocompatible materials to offer stable and durable therapeutic solutions for a variety of chronic conditions.

Ohana Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming reproductive health through innovative molecular techniques. Founded in 2015 and originally known as VL34, Inc., the company specializes in developing reproductive medicines aimed at enhancing sperm quality and function. Ohana Biosciences addresses infertility, mitigates inherited diseases, and aims to produce a long-lasting, reversible, and non-hormonal male contraceptive. By concentrating on sperm biology rather than egg biology, the company seeks to improve fertility rates, provide non-hormonal contraception options, and reduce pregnancy-related complications.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative gene therapies utilizing its proprietary Anellovector platform. This platform, based on the human commensal virome, addresses several limitations of existing gene therapies, including restricted access to diverse tissues, challenges in redosing, risks of genomic integration, and issues with tolerability. Founded in 2017 and previously known as VL46, Inc., Ring Therapeutics aims to expand the applications of gene therapy beyond traditional gene replacement. By enabling a broader range of therapeutic modalities and mechanisms, the company seeks to treat a variety of previously inaccessible diseases, including genetic disorders, ophthalmology, oncology, and metabolic conditions.

Invaio Sciences, Inc. is a multi-platform technology company headquartered in Cambridge, Massachusetts, with additional offices in Durham, North Carolina; Basel, Switzerland; and São Paulo, Brazil. Established in 2016, the company focuses on harnessing advanced sciences to address critical challenges in agriculture, nutrition, and the environment. Invaio's innovative technologies aim to reduce pesticide usage globally by enhancing the understanding of insect physiology and interdependent natural systems. By developing solutions that are both effective against pests and safe for beneficial species, Invaio seeks to create a positive impact on agriculture and human and animal health, positioning itself at the forefront of transformative practices in these fields.

Cellarity Inc is a therapeutics company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines through the analysis of cellular behaviors. Established in 2017, the company employs advanced genomic technologies, data science, and artificial intelligence to create a comprehensive platform that digitizes molecular information within cells. This approach allows Cellarity to investigate how cells function in both health and disease, aiming to address the complexities of various medical conditions. By leveraging single-cell technologies and machine learning, the company seeks to enhance the success rate and efficiency of drug discovery, ultimately designing therapies that effectively target the intricate dynamics of cellular behavior.

Cygnal Therapeutics, established in 2016 in Cambridge, Massachusetts, specializes in developing drugs that target and manipulate exoneural biology for treating cancer, immunological diseases, and regenerative processes. The company leverages a state-of-the-art neurotechnology platform to uncover novel aspects of neural function, enabling innovative therapeutic approaches. Cygnal was founded by Flagship Pioneering through its VentureLabs innovation foundry.

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Axcella Health Inc., established in 2008 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions. The company has clinical-stage candidates targeting muscle, neurodegenerative, and liver conditions, including AXA1665 for hepatic encephalopathy and AXA1125 for non-alcoholic steatohepatitis.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

Kaleido Biosciences is a clinical-stage healthcare company dedicated to harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the rapid and cost-effective discovery of Microbiome Metabolic Therapies (MMTs). These therapies aim to modulate the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates that target various diseases and conditions, addressing significant unmet medical needs.

Foghorn Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing innovative medicines that target genetically determined dependencies within the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control platform, Foghorn aims to manipulate gene expression to develop therapies for cancer and other serious diseases. The company is advancing multiple drug candidates, including FHD-286, a small-molecule enzymatic inhibitor designed for treating acute myeloid leukemia and uveal melanoma, and FHD-609, a protein degrader targeting BRD9 for synovial sarcoma. Additionally, Foghorn is engaged in preclinical and discovery programs that focus on selectively targeting BRM in non-small-cell lung cancer and developing modulators for ARID1B in bladder, ovarian, and endometrial cancers. Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics collaborates with Merck Sharp & Dohme Corp. to explore novel oncology therapeutics.

Rubius Therapeutics, Inc. is a biotechnology company focused on developing red cell therapeutics (RCTs) aimed at treating patients with severe diseases, including cancer, enzyme deficiencies, and autoimmune disorders. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. By creating a new class of medicines, Rubius Therapeutics seeks to address significant unmet medical needs through innovative approaches in the field of biotechnology.

Inzen Therapeutics is an early-stage biotechnology company focused on developing innovative treatments for chronic diseases. The company investigates cellular turnover as a significant factor in disease progression. Utilizing a platform that integrates mass spectrometry, machine learning, and advanced genetic and chemical biological technologies, Inzen aims to create novel therapeutic products. Its research targets various health conditions, including cancer, fibrotic disorders, immune-inflammatory disorders, metabolic disorders, and degenerative diseases. By leveraging these technologies, Inzen seeks to provide medical practitioners with effective treatment options for complex health issues.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Repertoire Immune Medicines, Inc. is a clinical stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company focuses on harnessing the power of T cells to develop innovative treatments for cancer, autoimmune diseases, and infectious diseases. By utilizing autologous T cells that are primed against specific cancer antigens and tethered to IL-15, Repertoire Immune Medicines aims to unlock and direct the human immune system to effectively prevent and treat various conditions. The company also specializes in characterizing T cell receptor (TCR)-antigen pairs and rationally designing targeted immune medicines, thereby enhancing the potential for effective therapies in serious health challenges.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

Kaleido Biosciences is a clinical-stage healthcare company dedicated to harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the rapid and cost-effective discovery of Microbiome Metabolic Therapies (MMTs). These therapies aim to modulate the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates that target various diseases and conditions, addressing significant unmet medical needs.

Omega Therapeutics, Inc. is a development-stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in developing genomic medicines aimed at curing diseases through precision tuning of the human genome. It utilizes its proprietary epigenomic programming platform to engineer a new class of programmable epigenetic medicines known as Omega Epigenomic Controllers. These controllers are designed to selectively regulate genomic activity, allowing for the downregulation or upregulation of genes to achieve therapeutic effects. Omega Therapeutics seeks to transform human medicine by harnessing the natural capacity of the genome to treat and cure various diseases.

Evelo Biosciences, Inc., established in 2015, is a biotechnology company based in Cambridge, Massachusetts. It specializes in the discovery and development of a novel class of medicines known as monoclonal microbials, which are orally delivered and designed to modulate systemic immunology and biology by interacting with human cells in the gut. Evelo's pipeline includes EDP1815, currently in a Phase 1b clinical trial for psoriasis and atopic dermatitis, and EDP1503, in a Phase 1/2 study for various cancer types, including colorectal, triple-negative breast, and melanoma. The company aims to apply this innovative approach across a broad range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory conditions, and cancer.

Rubius Therapeutics, Inc. is a biotechnology company focused on developing red cell therapeutics (RCTs) aimed at treating patients with severe diseases, including cancer, enzyme deficiencies, and autoimmune disorders. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. By creating a new class of medicines, Rubius Therapeutics seeks to address significant unmet medical needs through innovative approaches in the field of biotechnology.

CIBO Technologies, Inc. is a company that specializes in developing software products to model and simulate agricultural ecosystems, aimed at enhancing sustainable practices in agriculture. Its key offerings include Continuum DB, a distributed database for spatio-temporal modeling; BarnCAT, a computational agronomy toolkit; WhetherRain, an integrated weather simulation tool; and DirtPatch, a platform for environmental reconstruction. Additionally, CIBO provides TerraFarm for planetary-scale simulations and the Land Intelligence platform, which generates insights on agricultural parcels while offering access to publicly available data for various stakeholders in the agriculture sector. The company's solutions are designed to support a wide range of crops and serve multiple industries, including farm services, agribusiness, and sustainability. Founded in 2014 and based in Cambridge, Massachusetts, with additional offices in Saint Louis, East Lansing, and Minneapolis, CIBO aims to advance food system resilience and improve grower outcomes in the face of climate change.

Oasys Water, Inc. is a Boston-based company that specializes in forward osmosis technology aimed at addressing the global water crisis. Founded in 2008, the company has developed Engineered Osmosis, a proprietary platform that enhances the efficiency of desalination processes, making the treatment of saltwater more economical. Oasys Water's integrated systems focus on high recovery desalination, brine management, and zero liquid discharge solutions. By utilizing advanced resource recovery techniques, the company significantly lowers the cost of producing clean water and energy, enabling industries to optimize resource use while minimizing environmental impact. Oasys Water also maintains an office in Dubai to support its international operations.

Boragen Inc. is a biotechnology company based in Durham, North Carolina, founded in 2015. It specializes in the design and development of multifunctional small molecule boron solutions for applications in crop protection, animal health, and human health. Boragen's innovative synthetic chemistry platform enables the production of next-generation fungicides, including BAG8, a multisite fungicide, and BN2266, which targets mRNA processing. The company is also developing a dual function nematicide-fungicide for root protection and endo-parasiticides that can overcome resistance. By leveraging the unique properties of boron, Boragen aims to create sustainable agricultural solutions that reduce the probability of fungicide resistance and minimize chemical usage while maintaining efficacy across various sectors.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Incredible Foods, Inc. is a Boston-based manufacturer of non-dairy frozen products under the brand name perfectlyfree. Established in 2012, the company specializes in creating "Big 8 Allergy-Friendly" foods that cater to consumers seeking delicious and healthier options without common allergens. The product range includes fruit bites, frozen bites, and frozen pints, all made from natural, premium ingredients that are non-GMO and free from dairy, wheat, peanuts, tree nuts, eggs, soy, fish, and shellfish. Incredible Foods is dedicated to enhancing the lives of its customers by providing enjoyable and inclusive food experiences. The company operates as a subsidiary of Quantum Designs, LLC and changed its name from Wikifoods, Inc. in July 2016.

YourBio Health is focused on transforming the blood sampling and testing process by creating innovative products that enhance the interface between diagnostic medicine and healthcare consumers. The company has developed a unique blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy technology, this push-button device can be applied to the upper arm, enabling individuals to collect their blood with a simple press of a button. This one-step process is designed to eliminate barriers to acquiring critical diagnostic information, facilitating improved diagnoses and health outcomes. By making diagnostic testing accessible almost anywhere, YourBio Health aims to empower patients in their healthcare journey and enhance the overall experience for both patients and clinicians.

Denali Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151 for Parkinson's disease, and DNL747, a RIPK1 inhibitor targeting Alzheimer's and ALS. Denali's innovative approaches also include enzyme replacement therapy for MPS II and antibody transport vehicle programs aimed at addressing alpha-synuclein and Tau pathology. Established in 2013 and headquartered in South San Francisco, California, Denali collaborates with notable organizations including Takeda, Genentech, and the Michael J. Fox Foundation to leverage research and development in the field of neurodegeneration. The company aims to translate scientific insights into effective treatments, contributing to the ongoing effort to combat these debilitating conditions.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

TransMedics Group, Inc., established in 1998 and based in Andover, Massachusetts, is a commercial-stage medical technology company specializing in transforming organ transplant therapy for end-stage organ failure patients worldwide. The company's core product, the Organ Care System (OCS), is a portable, innovative technology that maintains donor organs outside the body in a near-physiologic state, replicating human-like conditions. This system includes OCS LUNG and OCS Heart, designed to preserve and optimize lungs and hearts respectively during transport, allowing for better assessment and improvement of organ condition. TransMedics also offers clinical services to enhance transplant volume, improve outcomes, and reduce learning curves for healthcare providers.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

TransMedics Group, Inc., established in 1998 and based in Andover, Massachusetts, is a commercial-stage medical technology company specializing in transforming organ transplant therapy for end-stage organ failure patients worldwide. The company's core product, the Organ Care System (OCS), is a portable, innovative technology that maintains donor organs outside the body in a near-physiologic state, replicating human-like conditions. This system includes OCS LUNG and OCS Heart, designed to preserve and optimize lungs and hearts respectively during transport, allowing for better assessment and improvement of organ condition. TransMedics also offers clinical services to enhance transplant volume, improve outcomes, and reduce learning curves for healthcare providers.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Rubius Therapeutics, Inc. is a biotechnology company focused on developing red cell therapeutics (RCTs) aimed at treating patients with severe diseases, including cancer, enzyme deficiencies, and autoimmune disorders. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. By creating a new class of medicines, Rubius Therapeutics seeks to address significant unmet medical needs through innovative approaches in the field of biotechnology.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Evelo Biosciences, Inc., established in 2015, is a biotechnology company based in Cambridge, Massachusetts. It specializes in the discovery and development of a novel class of medicines known as monoclonal microbials, which are orally delivered and designed to modulate systemic immunology and biology by interacting with human cells in the gut. Evelo's pipeline includes EDP1815, currently in a Phase 1b clinical trial for psoriasis and atopic dermatitis, and EDP1503, in a Phase 1/2 study for various cancer types, including colorectal, triple-negative breast, and melanoma. The company aims to apply this innovative approach across a broad range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory conditions, and cancer.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Axcella Health Inc., established in 2008 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions. The company has clinical-stage candidates targeting muscle, neurodegenerative, and liver conditions, including AXA1665 for hepatic encephalopathy and AXA1125 for non-alcoholic steatohepatitis.

Denali Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151 for Parkinson's disease, and DNL747, a RIPK1 inhibitor targeting Alzheimer's and ALS. Denali's innovative approaches also include enzyme replacement therapy for MPS II and antibody transport vehicle programs aimed at addressing alpha-synuclein and Tau pathology. Established in 2013 and headquartered in South San Francisco, California, Denali collaborates with notable organizations including Takeda, Genentech, and the Michael J. Fox Foundation to leverage research and development in the field of neurodegeneration. The company aims to translate scientific insights into effective treatments, contributing to the ongoing effort to combat these debilitating conditions.

Joule Unlimited, Inc., established in 2007, specializes in developing technology to produce low-carbon transportation fuels. The company's core process involves using solar energy to convert waste CO2 into renewable fuels, such as ethanol and hydrocarbons suitable for diesel, jet fuel, and gasoline. Joule Unlimited serves a global customer base, with operations in the United States, Europe, Australia, Mexico, and China. Notably, it has a strategic partnership with Audi. The company's products include Sunflow-E, a solar ethanol, and Sunflow-D, a solar diesel. Joule Unlimited is headquartered in Cambridge, Massachusetts, with additional offices in Los Angeles, California, and The Hague, the Netherlands, and production facilities in Hobbs, New Mexico.

Red Rock Biofuels is a company focused on developing processing plants that convert woody biomass into renewable diesel and jet fuels. Each of its refineries is engineered to utilize 175,000 dry tons of woody biomass annually, producing approximately 16 million gallons of finished fuel products. The company's proprietary technology begins with the gasification of the biomass to create synthesis gas, which is then cleaned and processed through a Fischer-Tropsch unit to produce liquid hydrocarbons. These hydrocarbons undergo hydroprocessing to yield jet, diesel, and naphtha fuels. By addressing climate change and promoting sustainable forestry practices, Red Rock Biofuels provides a low-carbon alternative for airlines and transportation companies seeking to reduce their carbon footprint. Founded by Jeff Manternach and Terry Kulesa, the company is headquartered in Colorado, United States.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

EcoSense Lighting specializes in advanced LED lighting solutions tailored for architectural and commercial applications. With over 100 years of combined experience, the company is recognized for its innovative technology, including a breakthrough dimming capability and advanced control systems that integrate seamlessly with various protocols such as DALI, DMX, 0-10V, and ELV. This integration allows businesses to enhance energy efficiency and achieve significant cost savings. EcoSense operates globally, with offices in the United States, the United Kingdom, and Hong Kong, and maintains its headquarters in Los Angeles. The company's commitment to quality and innovation positions it as a leader in the lighting industry.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, specializing in the development of microbiome therapeutics aimed at restoring health by correcting dysbiotic microbiomes. The company's lead product candidate, SER-109, is currently in Phase III clinical trials for the prevention of recurrent Clostridium difficile infection (CDI). In addition to SER-109, Seres is advancing several other therapeutic candidates: SER-287, which is in a Phase IIb study for ulcerative colitis; SER-401, a microbiome therapeutic in a Phase Ib study for use with checkpoint inhibitors in metastatic melanoma; SER-301 for inflammatory bowel disease; SER-262 for initial CDI recurrence; and SER-155 to address dysbiosis post-allogeneic hematopoietic stem cell transplants. Seres Therapeutics collaborates with notable institutions such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and has partnered with AstraZeneca to enhance its research and development efforts. Founded in 2010, Seres Therapeutics was previously known as Seres Health, Inc. until its name change in May 2015.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

Black Duck secures and manages open source software worldwide, eliminating open source security vulnerabilities and license compliance pain. With the rapid, widespread adoption of open-source software, Black Duck is a key component of Synopsys’ Software Integrity Platform, the most comprehensive solution for integrating security into the SDLC and software supply chain. Black Duck was established in 2002 and is based in Burlington, Massachusetts, United States.